日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18-49 Years of Age Enrolled at Center for Indigenous Health Sites

一项随机3期试验评估了15价肺炎球菌结合疫苗V114在6个月后接种23价肺炎球菌多糖疫苗(PPSV23)的安全性、耐受性和免疫原性(PNEU-DAY):在原住民健康中心招募的18-49岁成年人亚组分析

Hammitt, Laura L; Buchwald, Ulrike K; McCauley, Jennifer; Shekar, Tulin; Fu, Wei; Cheon, Kyeongmi; Sterling, Tina; Tamms, Gretchen; Banniettis, Natalie; Musey, Luwy; LeBlanc, Jason J; Weatherholtz, Robert; Riley, Dennie Parker; Denny, Estar; Tso, Carol; Roessler, Kristen; Santosham, Mathuram

A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM)

一项评估 15 价肺炎球菌结合疫苗 V114 在同种异体造血干细胞移植受者中的安全性、耐受性和免疫原性的 3 期随机、双盲、对照研究 (PNEU-STEM)

Wilck, Marissa; Cornely, Oliver A; Cordonnier, Catherine; Velez, Juan Diego; Ljungman, Per; Maertens, Johan; Selleslag, Dominik; Mullane, Kathleen M; Nabhan, Samir; Chen, Qiuxu; Dagan, Ron; Richmond, Peter; Daus, Caroline; Geddie, Kateasha; Tamms, Gretchen; Sterling, Tina; Patel, Shrita M; Shekar, Tulin; Musey, Luwy; Buchwald, Ulrike K

Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors

一项评估15价肺炎球菌结合疫苗V114(接种后6个月接种23价肺炎球菌多糖疫苗)在18-49岁高危成年人群中的安全性、耐受性和免疫原性的3期临床试验(PNEU-DAY):按基线风险因素进行的亚组分析

Hammitt, Laura L; Quinn, Dean; Janczewska, Ewa; Pasquel, Francisco J; Tytus, Richard; Reddy, K Rajender; Abarca, Katia; Khaertynova, Ilsiyar M; Dagan, Ron; Dawson, Rachel; McCauley, Jennifer; Shekar, Tulin; Fu, Wei; Pedley, Alison; Sterling, Tina; Tamms, Gretchen; Musey, Luwy; Buchwald, Ulrike K

The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C

15价肺炎球菌结合疫苗V114可诱导产生针对肺炎球菌6C血清型的交叉反应抗体。

Shi, Yaru; Nolan, Katrina M; Burton, Robert L; Shekar, Tulin; Murphy, Rocio D; Banniettis, Natalie; Musey, Luwy; Buchwald, Ulrike K

A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV

一项针对HIV感染儿童的3期临床试验,旨在评估V114(一种15价肺炎球菌结合疫苗)与23价肺炎球菌多糖疫苗联合接种的安全性和免疫原性。

Wilck, Marissa; Barnabas, Shaun; Chokephaibulkit, Kulkanya; Violari, Avy; Kosalaraksa, Pope; Yesypenko, Svitlana; Chukhalova, Iryna; Dagan, Ron; Richmond, Peter; Mikviman, Elena; Morgan, Leslie; Feemster, Kristen; Lupinacci, Robert; Chiarappa, Joseph; Madhi, Shabir A; Bickham, Kara; Musey, Luwy

Safety and Immunogenicity of V114 in Preterm Infants: A Pooled Analysis of Four Phase Three Studies

V114 在早产儿中的安全性和免疫原性:四项 III 期研究的汇总分析

Chapman, Timothy J; Patel, Shrita M; Flores, Sheryl A; Xu, Shengjie; Lupinacci, Robert; Shi, Yaru; Shekar, Tulin; Feemster, Kristen; Yi, Jumi; Tamms, Gretchen; Kaminski, Janusz; Bickham, Kara; Musey, Luwy; Buchwald, Ulrike K; Banniettis, Natalie

Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY)

V114(一种 15 价肺炎球菌结合疫苗)在 18-49 岁免疫功能正常的成年人(无论是否具有肺炎球菌疾病风险因素)中的免疫原性、安全性和耐受性:一项随机 3 期试验 (PNEU-DAY)

Hammitt, Laura L; Quinn, Dean; Janczewska, Ewa; Pasquel, Francisco J; Tytus, Richard; Rajender Reddy, K; Abarca, Katia; Khaertynova, Ilsiyar M; Dagan, Ron; McCauley, Jennifer; Cheon, Kyeongmi; Pedley, Alison; Sterling, Tina; Tamms, Gretchen; Musey, Luwy; Buchwald, Ulrike K

Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU)

在 ≥50 岁的健康成年人中,同时接种 15 价肺炎球菌结合疫苗 V114 与流感疫苗的安全性、耐受性和免疫原性:一项随机 3 期试验 (PNEU-FLU)

Severance, Randall; Schwartz, Howard; Dagan, Ron; Connor, Laurie; Li, Jianing; Pedley, Alison; Hartzel, Jonathan; Sterling, Tina M; Nolan, Katrina M; Tamms, Gretchen M; Musey, Luwy K; Buchwald, Ulrike K

Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older

在50岁及以上健康受试者中依次接种沛儿13™和肺炎球菌疫苗23™

Buchwald, Ulrike K; Andrews, Charles P; Ervin, John; Peterson, James T; Tamms, Gretchen M; Krupa, David; Ajiboye, Patrick; Roalfe, Lucy; Krick, Andrea L; Sterling, Tina M; Wang, Meihua; Martin, Jason C; Stek, Jon E; Kohn, Melvin A; Folaranmi, Temitope; Abeygunawardana, Chitrananda; Hartzel, Jonathan; Musey, Luwy K

A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants

一项针对健康婴儿的II期临床试验,比较了15价肺炎球菌结合疫苗V114与13价肺炎球菌结合疫苗的安全性、耐受性和免疫原性。

Platt, Heather L; Greenberg, David; Tapiero, Bruce; Clifford, Robert A; Klein, Nicola P; Hurley, David C; Shekar, Tulin; Li, Jianing; Hurtado, Kim; Su, Shu-Chih; Nolan, Katrina M; Acosta, Camilo J; McFetridge, Richard D; Bickham, Kara; Musey, Luwy K